Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disorder Clear all
Recruiting No phase listed Observational

Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

NCT03546387
View directory record Official record
Conditions
Pediatric Retinoblastoma, Retinoblastoma
Interventions
Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), California Verbal Learning Test, Children's Version, Beery Developmental Test of Visual Motor Integration, 6th edition, Grooved Pegboard Test, Behavior Assessment System for Children/Parent Report
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Choroidal Ischemia

NCT04356716
View directory record Official record
Conditions
Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions
Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
Drug · Other · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

NCT01292798
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 31, 2026, 4:01 PM EDT
Withdrawn Not applicable Interventional

Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration

NCT02024269
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
Adipose Derived Stem Cells
Biological
Lead sponsor
Bioheart, Inc.
Industry
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Sunrise, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 31, 2026, 4:01 PM EDT
Terminated Phase 4 Interventional

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902
View directory record Official record
Conditions
Diabetic Retinopathy, HIV
Interventions
Tesamorelin, Placebo-Control
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 2Phase 3 Interventional

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

NCT00590694
View directory record Official record
Conditions
Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Pacific Eye Associates
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 31, 2026, 4:01 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 4:01 PM EDT
Completed No phase listed Observational

Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

NCT03078231
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Not applicable Interventional

The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

NCT01364129
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ophthalmic Telemedicine
Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Wichita, Kansas • Pendleton, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 31, 2026, 4:01 PM EDT
Terminated Phase 1 Interventional

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

NCT00702819
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Vision Research Foundation
Other
Eligibility
30 Weeks to 36 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 31, 2026, 4:01 PM EDT
Completed No phase listed Observational

Imaging Parameters and DME Treatment Response

NCT02637245
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
No intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

NCT02357342
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus, Standard of Care intravitreal injections of anti-VEGF
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 31, 2026, 4:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of the Eye's Blood Vessels Using the Dynamic Vessel Analyzer (DVA)

NCT00783029
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 31, 2026, 4:01 PM EDT
Not listed Phase 4 Interventional

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

NCT00354445
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD)
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2007 · Synced Oct 31, 2026, 4:01 PM EDT
Active, not recruiting No phase listed Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 4:01 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

NCT06333249
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGR
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
8 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 31, 2026, 4:01 PM EDT
Terminated No phase listed Observational

Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

NCT05333055
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, Other Retinal Disorders
Interventions
Not listed
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Bellaire, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

NCT05747430
View directory record Official record
Conditions
Retinal Disease
Interventions
IRX-101, Providone-Iodine
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Greenwich, Connecticut • Madison, Mississippi • Erie, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Oct 31, 2026, 4:01 PM EDT
Completed No phase listed Observational

AMD Ryan Initiative Study (ARIS)

NCT03092492
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:01 PM EDT